Sitryx Therapeutics, an Oxford, UK-based biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, raised $39m in funding.
New investor Oxford Science Enterprises (OSE) joined existing healthcare investors SV Health Investors, Eli Lilly & Company (Lilly), Sofinnova Partners, Longwood Fund and GSK. Sanne de Jongh, Partner, Oxford Science Enterprises, joined Sitryx’ Board.
The company will use the proceeds to progress its immunometabolism-targeting therapies into clinical development.
Founded in 2018 by world-leading researchers in the field of immunology and metabolism, including Houman Ashrafian, Luke O’Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak and led by Neil Weir, Chief Executive Officer, Sitryx is building a broad and differentiated pipeline of proprietary therapies by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.
The company was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding. In 2020, Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the company.
FinSMEs
27/09/2023